Standardized broth microdilution and disk diffusion susceptibility tests for pefloxacin were performed on 585 clinical isolates. The 5-,ug pefloxacin disk is recommended, and the following breakpoints are proposed: susceptible, .19 mm (MIC, .2.0 ,ug/ml); resistant, <15 mm (MIC, >4.0 ,ug/ml); and intermediate, 16 to 18 mm.
90% (MIC90s) of the isolates within each species are shown * Corresponding author.
in Table 1 , together with the MIC90s of four comparative quinolones. Despite attempts to increase the proportion of resistant isolates, the MIC90s rarely differed by more than one twofold concentration from those in previously published studies (1, 3) .
Scattergrams of pefloxacin and norfloxacin MICs plotted against pefloxacin 5-,ug disk diffusion zone diameters ( Fig. 1 ) and norfloxacin 10-jig disk diffusion zone diameters (data not shown) were made. Norfloxacin was used as a control for the pefloxacin procedures, since its performance characteristics are well described (2) . The regression formula for the norfloxacin data was essentially identical to that previously published (2) . The application of National Committee for Clinical Laboratory Standards breakpoints (5) to the norfloxacin data yielded a minimal number of interpretive errors (7.3% minor errors, 0.2% very major errors, and no major errors).
For pefloxacin, -2.0 jig/ml was chosen as the susceptible MIC breakpoint, and >4.0 ,ug/ml was chosen as the resistant MIC breakpoint. These choices were based on somewhat scanty published pharmacokinetic data in humans indicating that a single oral dose of 400 mg of pefloxacin will achieve mean peak levels in plasma of 3.8 jig/ml (4) . With comparable oral doses given every 12 h to two patients with meningitis, Wolff et al. found peak levels in plasma of 8.2 and 10.0 jig/ml after the third dose, with corresponding peak levels in cerebrospinal fluid of 3.8 and 3.0 jig/ml (7) . The anticipated clinical oral doses of 600 and 800 mg, when given orally to male volunteers, resulted in maximal concentrations in plasma of 5.4 ± 1.0 and 6.06 ± 0.75 ,ug/ml, respectively (Bruce L. Moskovitz, personal communication). It appears, therefore, that until more pharmacokinetic data are available for the oral route, the MIC breakpoints selected above are reasonable.
The pefloxacin regression formula based on the 540 onscale datum points in Fig. 1 and on 
